Aspergillus fumigatus (A. fumigatus) is a common airborne fungus and significant human opportunistic pathogen, causing invasive aspergillosis that results in approximately 14,000 hospitalisations and over 1,200 deaths annually in the United States alone. The risk of A. fumigatus infection increases with the use of hormones, immunosuppressants, broad-spectrum antibiotics, and the incidence of cancer and immunodeficiency conditions. Every year, it is estimated that there exist globally around 5 million cases of allergic bronchopulmonary aspergillosis, 3 million cases of chronic pulmonary aspergillosis, and between 250,000 to 400,000 cases of invasive aspergillosis.
In a single study conducted at Jiangsu Provincial People’s Hospital in China, analysis of 561 clinical isolates of A. fumigatus revealed that a significant number (78.97%) of identified cases were individuals within the 51-90 age demographic. Among these, patients were predominantly male (82.35%) as compared to female (17.65%). The greatest detection rates were within the intensive care unit and the internal medicine department, comprising 81.11% of the total.
Further evaluation of these infections showed a significant difference in where the infections were primarily located, with lower respiratory tract infections accounting for 95.37% across all groups. Varying epidemiological characteristics observed across different infection types highlighted the necessity for medical institutions to develop targeted prevention and control measures for A. fumigatus infections.
The research demonstrated an escalating trend in A. fumigatus detection rates from 2021 to 2023, which emphasizes the importance of continuous surveillance and appropriate infection control measures to tackle this potential public health issue. The study also provides insights into the epidemiological distribution of invasive A. fumigatus infections and sheds light on the need for effective strategies to prevent and control fungal infections in clinical settings.